Remifentanil

Drug Profile

Remifentanil

Alternative Names: Aruchiba; GI 87084; GI 87084B; GR 87084; JNJ-268229; Remifentanil hydrochloride; Remifentanyl; Ultiva

Latest Information Update: 13 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Developer Abbott Laboratories; GlaxoSmithKline; Janssen Pharmaceutical KK
  • Class Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaesthesia; Pain

Most Recent Events

  • 04 Oct 2016 Launched for Anaesthesia (In adolescents, In children, In infants) in Japan (IV)
  • 12 Sep 2016 Aspen acquires remifentanil from GlaxoSmithKline
  • 26 Aug 2016 Registered for Anaesthesia (In adolescents, In children, In infants) in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top